Amphastar Pharmaceuticals Inc has a consensus price target of $53.5, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, B of A Securities, and Jefferies on March 5, 2024, November 17, 2023, and July 25, 2023. With an average price target of $64.33 between JP Morgan, B of A Securities, and Jefferies, there's an implied 44.67% upside for Amphastar Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/05/2024 | AMPH | Buy Now | Amphastar Pharma | $44.47 | 34.92% | JP Morgan | Ekaterina Knyazkova | → $60 | Initiates | → Overweight | Get Alert |
11/17/2023 | AMPH | Buy Now | Amphastar Pharma | $44.47 | 41.67% | B of A Securities | Jason Gerberry | → $63 | Initiates | → Neutral | Get Alert |
07/25/2023 | AMPH | Buy Now | Amphastar Pharma | $44.47 | 57.41% | Jefferies | Glen Santangelo | → $70 | Reinstates | Buy → Buy | Get Alert |
05/17/2023 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -1.06% | Wells Fargo | Jacob Hughes | $40 → $44 | Maintains | Equal-Weight | Get Alert |
10/25/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -10.05% | Piper Sandler | David Amsellem | $43 → $40 | Maintains | Overweight | Get Alert |
10/21/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -19.05% | Jefferies | Glen Santangelo | — | Assumes | → Buy | Get Alert |
07/29/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -1.06% | Capital One | Tim Chiang | → $44 | Initiates | → Overweight | Get Alert |
03/15/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -28.04% | Wells Fargo | Jacob Hughes | $23 → $32 | Maintains | Equal-Weight | Get Alert |
03/11/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -21.3% | Piper Sandler | David Amsellem | $28 → $35 | Maintains | Overweight | Get Alert |
01/07/2022 | AMPH | Buy Now | Amphastar Pharma | $44.47 | -37.04% | Piper Sandler | David Amsellem | $21 → $28 | Upgrade | Neutral → Overweight | Get Alert |
The latest price target for Amphastar Pharma (NASDAQ: AMPH) was reported by JP Morgan on March 5, 2024. The analyst firm set a price target for $60.00 expecting AMPH to rise to within 12 months (a possible 37.87% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Amphastar Pharma (NASDAQ: AMPH) was provided by JP Morgan, and Amphastar Pharma initiated their overweight rating.
The last upgrade for Amphastar Pharmaceuticals Inc happened on January 7, 2022 when Piper Sandler raised their price target to $28. Piper Sandler previously had a neutral for Amphastar Pharmaceuticals Inc.
There is no last downgrade for Amphastar Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.
While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a initiated with a price target of $0.00 to $60.00. The current price Amphastar Pharma (AMPH) is trading at is $43.52, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.